Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry‐Based Real‐World Study
European Journal of Neurology · 2026-04 · 33 (4)
DOI: 10.1111/ene.70597 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 09.04.2026. Verfasst von Christian Lampl und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Stroke Unit, Konventhospital Barmherzige Brüder Linz, Linz, Austria. Hauptthemen laut MEDLINE: Migraine Disorders, Hypertension, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Recent post‐marketing studies have indicated a possible association between anti‐CGRP receptor monoclonal antibodies (anti‐CGRP‐mAbs) used for migraine prophylaxis and an increased risk of hypertension (HT).
Methods
We performed a retrospective real‐world exploratory study, including individuals with a confirmed diagnosis of migraine who were treated with erenumab, an anti‐CGRP receptor (r)‐mAb, for at least 12 months. Inclusion was limited to individuals with complete clinical records and regular follow‐up, with at least one visit every 3 months and data available to assess treatment outcomes. Patients were excluded if they had previously received anti‐CGRP mAbs or gepants for migraine prevention before starting the current therapy, were on any concomitant baseline migraine preventive treatment, or did not complete the 12‐month follow‐up visits.
Results
One hundred twenty‐five participants were eligible and included in the analysis. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were compared between baseline and follow‐up visits, conducted every 3 months for up to 24 months while the patient was on treatment. Individuals treated with erenumab initially received 70 mg, administered subcutaneously every 4 weeks. Throughout the 12‐month treatment period, blood pressure (BP) measurements remained stable and within normal physiological ranges, indicating no significant hypertensive effect. Analysis across multiple visits showed that SBP ranged from 118 to 121 mmHg, while DBP stayed between 78 and 80 mmHg. Erenumab treatment over 24 months in 54 patients demonstrated stable BP with no notable hypertensive effects.
Conclusions
This study did not find sufficient evidence that treatment with erenumab leads to the development of HT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Stroke Unit, Konventhospital Barmherzige Brüder Linz, Linz, Austria.
- Headache Medical Center, Linz, Austria.
- American Center for Psychiatry & Neurology, Abu Dhabi, UAE.
- Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
ORCID-Profile: Christian Lampl, Reem Suliman, Viktoria Tischler-Strasser, Antoinette MaassenVanDenBrink, Taoufik Alsaadi
Zitieren
APA
Lampl, C., Suliman, R., Tischler-Strasser, V., MaassenVanDenBrink, A., & Alsaadi, T. (2026). Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry‐Based Real‐World Study. European Journal of Neurology, 33(4). https://doi.org/10.1111/ene.70597
Vancouver
Lampl C, Suliman R, Tischler-Strasser V, MaassenVanDenBrink A, Alsaadi T. Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry‐Based Real‐World Study. European Journal of Neurology. 2026;33(4). doi:10.1111/ene.70597
BibTeX
@article{Lampl2026,
author = {Lampl, Christian and Suliman, Reem and Tischler-Strasser, Viktoria and MaassenVanDenBrink, Antoinette and Alsaadi, Taoufik},
title = {Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry‐Based Real‐World Study},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {4},
doi = {10.1111/ene.70597}
}
EUVIMED